|
Name
|
Authors
|
Characteristics
|
Diffenrentiation capacity
|
|
ES cells
|
Numerous
|
Capable of mass culture.
Immunosuppressive agents
required for allogeneic
transplantation.
|
Can differentiate into wide variety
cells, but cells capable of
differentiating in the early embryonic
period are to obtain in vitro.
|
|
Bone marrow
mesenchymal
stem cells
|
Fukuda et al,
Keio Univ.
|
Culture method relatively
easy.
|
Osteoblasts, chondroblasts,
adipocytes, cardiomyocytes, etc.
|
|
MAPC cells
|
Verfeille et al,
University
of Minnesota
|
Culture¡¡method extremely¡¡difficult.
Mass culture impossible.
|
Can differentiate into wide variety cells
including neurons, hepatocytes,
skeletal muscle cells.
|
|
Myocardial tissue
stem cells
(c-Kit cells)
|
Anversa et al,
State University
of New York
|
Isolation difficult.
Mass culture impossible.
|
Myocardium, smooth muscle, vascular
endothelial cells.
|
|
Myocardial tissue
stem cells
(Sca-1 cells)
|
Schneider et al,
Baylor University
|
Isolation difficult.
Mass culture impossible.
|
Myocardium
|
|
Cd133 cells
|
Rafii S, Lyden D.
Rehman J, Li J, Orschell CM, March KL.
|
neovascularization and differentiate into mature
endothelial cells.
|
Endothelial cell
|
|
EPC
|
Asahara T, Kawamoto A.
|
neovascularization and differentiate into mature
endothelial cells
releasing paracrine factors.
|
Endothelial cell
|
|
Study
|
[n] and
Cell Type
|
Delivery
|
Time After
AMI
|
Outcomes
|
||
|
Improved
|
No Change
|
|||||
|
Strauer et al
|
10 treated, 10 controls* MNC
|
IC
|
5?9 days
|
Regional wall motion?;
|
Global LVEF;
|
|
|
Infarct size¡ý Perfusion?
|
LVEDV?
|
|||||
|
TOPCARE-AMI
|
29 MNC, 30 CPC, MNC
11 controls* CPC
|
IC
|
5_2 days
|
Regional wall motion?;
|
LVEDV?
|
|
|
Global LVEF?;
|
||||||
|
Infarct size 2?;
|
||||||
|
Coronary flow?
|
||||||
|
Fernandez-Aviles et al
|
20 treated, 13 controls* MNC
|
IC
|
14_6 days
|
Regional wall motion?;
|
LVEDV?
|
|
|
Global LVEF?
|
||||||
|
Kuethe et al
|
5 treated MNC
|
IC
|
6 days
|
Regional wall motion?;
|
||
|
Global LVEF?
|
||||||
|
BOOST
|
30 treated, 30 controls NC
|
IC
|
6_1 day
|
Regional wall motion;
|
LVEDV; Infarct size
|
|
|
Global LVEF
|
||||||
|
Chen et al
|
34 treated, 35 controls MSC
|
IC
|
18 days
|
Regional wall motion;
|
||
|
Global LVEF;
|
||||||
|
Infarct size ¡ý;
|
||||||
|
LVEDV ¡ý
|
||||||
|
Vanderheyden et al
|
12 treated, 10 controls* CD133?
|
IC
|
14_6 days
|
Regional wall motion?;
|
||
|
Global LVEF?; Perfusion?
|
||||||
|
Study
|
[n]
|
LVEF
|
Cell Type
|
Time after
|
Delivery
|
Outcomes?
|
|
MI
|
||||||
|
Menasche et al
|
10 treated
|
24_4£¥
|
Myoblasts
|
3?228
months
|
Transepicardial
(during CABG)*
|
Regional wall motion ¡ü;
Global LVEF¡ü
|
|
Herreros et al
|
11 treated
|
36_8£¥
|
Myoblasts
|
3?168
months
|
Transepicardial
(during CABG)?
|
Regional wall motion ¡ü;
Global LVEF ¡ü; Viability in infarct area ¡ü
|
|
Siminiak et al
|
10 treated
|
25?40£¥
|
Myoblasts
|
4?108
months
|
Transepicardial
(during CABG)?
|
Regional wall motion ¡ü;
Global LVEF ¡ü
|
|
Chachques et al
|
20 treated
|
28_3£¥
|
Myoblasts
|
not
reported
|
Transepicardial
(during CABG)*
|
Regional wall motion ¡ü;
Global LVEF ¡ü; Viability in
infarct area ¡ü
|
|
Smits et al
|
5 treated
|
36_11£¥
|
Myoblasts
|
24?132
months
|
Transendocardial
(guided by EMM)
|
Regional wall motion ¡ü;
Global LVEF ¡ü
|
|
Stamm et al
|
12 treated
|
36_11£¥
|
CD133?
|
3?12
weeks
|
Transepicardial
(during CABG)*
|
Global LVEF ¡ü; LVEDV ¡ý;
Perfusion ¡ü
|
|
Assmus et al
|
51 MNC, 35 CPC, 16 controls
|
40_11£¥
|
MNC CPC
|
3?144 months
|
IC
|
Global LVEF ¡ü; (only in MNC group)
|
Ä¿Ç°ÔÚ¶¯ÎïʵÑéÖеĸ±×÷Óñ¨µÀÊǷdz£Éٵġ£ÔÚ¹·µÄÐļ¡¹£ËÀÄ£ÐÍÖУ¬¾¹Ú×´¶¯Âö×¢Èë¼ä³äÖʸÉϸ°ûºó¿ÉÒÔ¼ûµ½Î¢¹£ËÀ£¬ST¶Î̧¸ßºÍT²¨µÄ¸Ä±ä¡£Yoon±¨µÀÐļ¡¹£ËÀÄ£Ð͵ĴóÊó×¢Èë¹ÇËè¸Éϸ°ûºó·¢ÏÖ¹£ËÀÐļ¡ÖÜΧ´æÔÚ¸Éϸ°ûÀ´Ô´µÄ¸Æ»¯µã¡£Ä¿Ç°ÑÏÖصĸ±×÷Ó÷¢ÉúÓÚÁÙ´²ÊµÑéÖУ¬Ó¦ÓùÇ÷À¼¡×æϸ°ûÒÆÖ²µÄ²¡ÈËÓÚÒÆÖ²ºóµÄ11ÖÁ22Ìì¼ä·¢ÉúÁ˳ÖÐøµÄÑÏÖØÊÒÐÔÐÄÂÉʧ³££¬Õâ¿ÉÄÜÊÇÓÉÓÚ¹Ç÷À¼¡×æϸ°û·Ö»¯ºóµÄ¼¡Ï¸°ûȱ·¦Ðļ¡Ï¸°ûÖ®¼äµÄÈòÅÌËùÖ¡£Ó¦ÓùÇËèÀ´Ô´µÄ¸Éϸ°ûÒÆÖ²ËäûÓз¢ÉúÑÏÖصÄÐÄÂÉʧ³££¬µ«Í¨¹ýÐÄÄÚĤ·½Ê½ÒÆÖ²µÄÊÔÑéÈÔӦעÒâÐÄÂÉʧ³£·¢ÉúµÄΣÏÕ¡£Ó¦ÓùÇËè¸Éϸ°ûÒÆÖ²ÁîÈ˱Ƚϵ£ÐĵĿÉÄÜÊÇÖ×ÁöºÍÁöÑùѪ¹ÜÐγɣ¬µ«Ä¿Ç°ÉÐûÓд˷½ÃæµÄ±¨µÀ¡£ÁíÒ»¸ö½ÏÑÏÖصĸ±×÷Óü´Ï¸°ûÒò×Ó¶¯Ô±¸Éϸ°ûÒÆֲʱµ¼Ö¹Ú×´¶¯ÂöÏÁÕ£¬Õâ¸öÁÙ´²ÊÔÑéÄ¿Ç°ÒѾֹͣ¡£
°æȨÉùÃ÷£º±¾ÍøÕ¾ËùÓÐÄÚÈÝ£¬·²×¢Ã÷À´Ô´Îª¡°Ñ°Ò½ÎÊÒ©Íø-Ò½Âö¡±£¬°æȨ¾ù¹éÑ°Ò½ÎÊÒ©ÍøËùÓУ¬»¶ÓתÔØ£¬×ªÔØÇë×¢Ã÷×÷Õߺͳö´¦£¬·ñÔò½«×·¾¿·¨ÂÉÔðÈΡ£±¾Íø×¢Ã÷À´Ô´ÎªÆäËûýÌåµÄÄÚÈÝΪתÔØ£¬°æȨ¹éÔ×÷ÕßËùÓУ¬ÈçÓÐÇÖ·¸°æȨ£¬Ç뼰ʱÁªÏµÎÒÃÇ¡£
